INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-f ...

VistaGen Therapeutics (NasdaqCM:VTGN) Q3 2026 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsElemer Piros - Managing DirectorJoshua Prince - COOMark McPartland - Senior Vice President, Investor RelationsNick Tressler - CFOShawn K. Singh - President and CEOConference Call ParticipantsAndrew Fein - Managing Director and Senior Biotechnology AnalystNone - AnalystNone - AnalystOperatorGood day, everyone. Thank you for standing by. Welcome to the Vistagen Therapeutics Fiscal Year 2026, third qua ...

Bio-Rad Laboratories (NYSE:BIO) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsEdward Chung - VP of Investor RelationsJon DiVincenzo - President and COONorman Schwartz - CEORoop Lakkaraju - EVP and CFOConference Call ParticipantsDan Leonard - Managing Director and Senior Equity Research AnalystJack Meehan - Partner and Senior Equity Research AnalystTycho Peterson - Managing Director and Senior Equity Research AnalystOperatorGood day, everyone, and welcome to the Bio-Rad fourth quart ...

VistaGen Therapeutics (NasdaqCM:VTGN) Q3 2026 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsJoshua Prince - COOMark McPartland - Senior Vice President, Investor RelationsNick Tressler - CFOShawn K. Singh - President and CEOConference Call ParticipantsAndrew Fein - Managing Director and Senior Biotechnology AnalystMyles Minter - Biotech Equity Research AnalystNone - AnalystOperatorGood day, everyone. Thank you for standing by. Welcome to the Vistagen Therapeutics Fiscal Year 2026, third qua ...

Bio-Rad Laboratories (NYSE:BIO) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsEdward Chung - VP of Investor RelationsJon DiVincenzo - President and COONorman Schwartz - CEORoop Lakkaraju - EVP and CFOConference Call ParticipantsDan Leonard - Managing Director and Senior Equity Research AnalystJack Meehan - Partner and Senior Equity Research AnalystTycho Peterson - Managing Director and Senior Equity Research AnalystOperatorGood day, everyone, and welcome to the Bio-Rad fourth quart ...

Financial Data and Key Metrics Changes - Net sales for Q4 2025 were approximately $693 million, a 3.9% increase from $668 million in Q4 2024. On a currency neutral basis, this represents a 1.7% year-over-year increase driven by the clinical diagnostics segment [11] - Full year net sales for 2025 were $2.583 billion, a 0.7% increase from $2.567 billion in 2024. On a currency neutral basis, sales were essentially flat compared to 2024 [18] - Q4 GAAP gross margin was 49.8%, down from 51.2% in Q4 2024. Non-GAAP gross margin was 52.5%, compared to 53.9% in the previous year [13][14] - Full year non-GAAP gross margin was 53.3%, down from 55% in 2024, primarily due to reduced fixed manufacturing absorption and higher material costs [20] Business Segment Data and Key Metrics Changes - Clinical diagnostics segment sales in Q4 2025 were approximately $425 million, an increase of 8.4% on a reported basis from $393 million in Q4 2024, driven by higher sales of quality control and blood typing products [13] - Life science segment sales in Q4 2025 were $268 million, a 2.6% decrease from $275 million in Q4 2024, impacted by a constrained academic research and biotech funding environment [11] - The ddPCR portfolio posted mid-single-digit year-over-year growth in Q4, driven by the success of the QX700 platform [12] Market Data and Key Metrics Changes - Currency neutral sales decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific [12] - In biopharma, funding conditions improved during the second half of 2025, with expectations for a modest recovery in 2026 [9] - Academic institutions remain cautious in spending, focusing on maintaining staffing levels rather than purchasing capital equipment [8] Company Strategy and Development Direction - The company plans to advance several product launches in 2026, including an IVD version of the QX600 and additional high-value ddPCR assays across oncology [10] - Bio-Rad remains focused on disciplined innovation as a core part of its long-term growth strategy [9] - The company is looking for additional assets to help accelerate top-line growth and margin expansion [31] Management's Comments on Operating Environment and Future Outlook - Management noted early signs of stabilization across core markets, with improvements in NIH funding and biopharma funding [29] - The company is confident that actions taken to improve operational performance and expand margins will translate into better financial results over time [10] - Management remains cautious about the potential impact of policy developments in China on reimbursement rates [6] Other Important Information - Free cash flow for the full year 2025 improved to approximately $375 million, representing a conversion ratio of 138% for free cash flow to non-GAAP net income [23] - The company retired 1.2 million shares through its buyback program at a total cost of approximately $296 million during 2025 [23] Q&A Session Summary Question: Can you elaborate on the ddPCR business growth and the contribution from Stilla? - Management indicated that the strong growth was driven by the QX700 platform and a large installed base, with ongoing reagents being a significant part of the portfolio [35][36] Question: What are the recent changes affecting Process Chromatography? - Management explained that changes in vaccine production strategies and government regulations impacted demand, leading to a conservative outlook for this segment [38] Question: What is the outlook for operating margins in 2026? - Management provided a realistic outlook, factoring in the impact of Process Chromatography and operational improvements, guiding for an operating margin between 12% and 12.5% [39][41] Question: Why is clinical diagnostics growth muted compared to pre-COVID levels? - Management attributed the muted growth to a mix of product performance and geographic factors, particularly reliance on markets like China [60] Question: What is the long-term growth outlook for Process Chromatography? - Management suggested a possibility of returning to low single-digit growth by 2027, with potential for acceleration depending on customer transitions from clinical to commercial phases [62]

Vertex Pharmaceuticals (NasdaqGS:VRTX) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBrian Abrahams - Managing Director and Global Sector Head of Healthcare Research Full-timeCharlie Wagner - COO and CFOCory Kasimov - Senior Managing DirectorDuncan McKechnie - Chief Commercial OfficerEvan Seigerman - Managing Director and Head of Healthcare ResearchGeoff Meacham - Managing DirectorMichael Yee - Global Head of Biotechnology Research and Managing DirectorReshma Kewalramani - CEO and ...

Financial Data and Key Metrics Changes - 10x Genomics reported $166 million in revenue for Q4 2025, representing a 1% increase year-over-year and exceeding the high end of guidance [18] - Full-year revenue for 2025 was $599 million, excluding $44 million from patent litigation settlements [4] - Gross margin improved to 68% in Q4 2025 from 67% in the prior year, driven by lower inventory write-downs and costs [20] - Operating expenses decreased by 18% in Q4 2025, reflecting cost discipline and efficiency [21] - Cash balance increased by $130 million year-over-year, ending 2025 with $523 million [21] Business Line Data and Key Metrics Changes - Total consumables revenue grew by 6%, with single-cell consumables revenue up 3% and spatial consumables revenue up 14% [19] - Single-cell consumables volumes grew at a double-digit rate each quarter, driven by the adoption of lower-cost products like FLEX [5] - Spatial consumables revenue growth was primarily driven by the success of the Xenium platform [6] Market Data and Key Metrics Changes - Revenue from the Americas declined by 6%, while EMEA and APAC regions grew by 7% and 9%, respectively [20] - The operating environment remained challenging, particularly in the U.S. academic and government funding sectors, impacting customer purchasing decisions [4][20] Company Strategy and Development Direction - The company is focused on continuous innovation and expanding its product offerings, particularly in single-cell and spatial technologies [10] - 10x Genomics aims to leverage advancements in AI and biology measurement technologies to drive growth [11] - The company is pursuing clinical applications for diagnostics, collaborating with academic medical centers to generate clinical evidence [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position amidst ongoing funding challenges, noting a gradual improvement in customer sentiment [27] - The outlook for 2026 includes revenue guidance of $600 million to $625 million, reflecting expectations of continued growth in single-cell and spatial consumables [22] - Management acknowledged the systemic turbulence in research funding dynamics but noted recent NIH budget approvals as a positive sign [22] Other Important Information - The company launched several new products in 2025, including the FLEX APEX assay, which has been well-received by customers [8] - The company is seeing strong demand for its Xenium platform, which is expected to continue driving growth in spatial analysis [10] Q&A Session Summary Question: Can you comment on ordering patterns and expectations for academic and pharma? - Management noted that the environment remains steady but cautious, with ongoing uncertainty in academic funding impacting purchasing decisions [27] Question: How did volume growth and pricing impact single-cell consumables? - Management indicated that while volume growth was strong, pricing dynamics are complex, with various factors influencing the overall revenue guidance for 2026 [31][35] Question: What are the expectations for clinical translational space? - Management highlighted a hybrid strategy to enable clinical evidence generation while also pursuing direct clinical applications [48][50] Question: How is the company addressing competitive dynamics? - Management expressed confidence in their competitive position, citing continuous innovation and strong customer sentiment for their products [76] Question: What is the outlook for the Visium platform? - Management acknowledged that while Visium did not grow in 2025, they will continue to support its applications while focusing on the growth of the Xenium platform [80]

this source### PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026[PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year ...]### PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference[PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief...][More Re ...

Fourth-Quarter and Full-Year 2025 Results Supplemental Earnings Results Presentation February 12, 2026 Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management's goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters. Forward looking statements generally can be i ...